Recombinant Biotinylated Human Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein, His,Avitag™&Tag Free, 25 µg

Background
Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

Source
Recombinant Biotinylated Human ITGAV&ITGB8 Heterodimer Protein, His,Avitag&Tag Free (IT8-H82W5) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 992 (ITGAV) & Glu 43 - Arg 684 (ITGB8) (Accession # NP_002201.1 (ITGAV) & NP_002205.1 (ITGB8)).
Predicted N-terminus: Phe 31 (ITGAV) & Glu 43 (ITGB8)

Molecular Characterization
Biotinylated Human ITGAV&ITGB8 Heterodimer Protein, His,Avitag&Tag Free, produced by co-expression of ITGAV and ITGB8, has a calculated MW of 114.7 kDa (ITGAV) and 76.5 kDa (ITGB8). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and an Avi tag (Avitag™) and subunit ITGB8 contains no tag but a basic tail at the C-terminus. The non-reducing (NR) protein migrates as 135 kDa (ITGAV) and 80 kDa (ITGB8) respectively due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH8.0 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "Generation of induced pluripotent stem cells from rat fibroblasts and optimization of its differentiation into mature functional neurons"
Kuwar, Zhang, McQuiston et al
J Neurosci Methods (2024) 406, 110114
(2)  "Mechanism of RGD-conjugated nanodevice binding to its target protein integrin αVβ3 by atomistic molecular dynamics and machine learning"
Frigerio, Donadoni, Siani et al
Nanoscale (2024) 16 (8), 4063-4081
(3)  "Delineating Pixantrone Maleate's adroit activity against cervical cancer proteins through multitargeted docking-based MM\GBSA, QM-DFT and MD simulation"
Almasoudi, Nahari, Alhazmi et al
PLoS One (2023) 18 (12), e0295714
Showing 1-3 of 334 papers.